We claim:

1. A compound of the formula



I

or a pharmaceutically acceptable acid addition salt thereof wherein R^1 is selected from the group consisting of hydrogen and alkyl C_1 to C_{10} ; and wherein n is an integer from 1 to 5.

2. A compound according to claim 1 wherein R^1 is ethyl.

3. A compound according to claim 1 wherein said pharmaceutically acceptable acid addition salt is selected from the group consisting of chloride, mesylate, acetate, fumarate, succinate, maleate, besylate, citrate, tartrate and sulfate.

4. A compound according to claim 3 wherein said pharmaceutically acceptable acid addition salt is the hydrochloride salt.

5. A compound according to claim 3 wherein said pharmaceutically acceptable acid addition salt is the mesylate salt.

6. A compound according to claim 1, wherein said compound is 4-{5-[2-(4-benzo[*d*]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-2-oxo-2,3-dihydro-indol-1-yl}-4-oxo-butyric acid ethyl ester, hydrochloride salt.

7. A process for preparing a compound of formula



I

comprising reacting a compound of formula



II

with a base wherein R^1 is selected from the group consisting of hydrogen and alkyl C_1 to C_{10} ; and wherein n is an integer from 1 to 5.

8. The process of claim 7 wherein said compound of formula II is prepared by reacting a compound of the formula



III

with an alcohol of formula R^1OH in the presence of concentrated hydrochloric acid wherein M is Ca or Ba; and R^1 is selected from the group consisting of hydrogen and alkyl C_1 to C_{10} ; and wherein n is 1 to 5.

9. The process of claim 8 wherein said compound of formula III is prepared by reacting a compound of formula



IV

with calcium hydroxide or barium hydroxide wherein R^2 is C_1-C_{10} alkyl and n is an integer from 1 to 5.

10. The process of claim 9 wherein said compound of formula IV is prepared by reacting a compound of formula



V

with an anhydride acylating agent.

11. The process of claim 10 wherein said acylating agent is an anhydride acylating agent having the formula



VI

wherein R^2 is C_1-C_{10} alkyl and n is an integer from 1 to 5.

12. The process of claim 10 wherein said anhydride acylating agent reacts with the compound of formula V in the presence of magnesium bromide-diethyl ether etherate and an organic base.

13. The process of claim 11 wherein said anhydride acylating agent is the anhydride having the formula



VII

14. The process of claim 12 wherein said organic base is triethylamine.

15. The process of claim 7 wherein said base is selected from the group consisting of alkali metal bicarbonates, alkali metal carbonates, C-1 to C-6 trialkylamines; and heterocyclic bases selected from the group consisting of pyridine, lutidine and picoline.

16. The process of claim 15 wherein said base is sodium bicarbonate.

17. A pharmaceutical composition having neuroleptic activity comprising the compound according to claim 1 in an amount effective in the treatment of neuroleptic diseases, and a pharmaceutically acceptable carrier.

18. A method of treating neuroleptic diseases which comprises administering to a subject in need of such treatment a neuroleptic active amount of the compound according to claim 1.

19. A compound of formula



IV

or a pharmaceutically acceptable acid addition salt thereof wherein R^2 is C_1-C_{10} alkyl and n is an integer from 1 to 5.

20. A compound according to claim 19 wherein said compound is succinic acid 5-[2-(4-benzo[*d*]isothiazol-3-yl-piperzin-1-yl) ethyl] -6-chloro-1-(3-ethoxycarbonyl-propionyl)-1*H*-indoyl-2-yl ester ethyl ester.

21. A compound of the formula



III

wherein M is Ca or Ba and n is an integer from 1 to 5.

A compound according to claim 21 wherein said compound is 4-{5-[2-(-benzo[*d*]isothiazol-3-yl-piperzin-1-yl)ethyl]-6-chloro-2-oxo-2,3-dihydroindol-1-yl}-4-oxo-butyric acid calcium salt.

A compound according to claim 21 wheein said compound is 4-{5-[2-(4-benzo[*d*]isothiazol-3-yl-piperazin-1-yl)ethyl]-6-chloro-2-oxo-2,3-dihydro-indol-1-yl}-4-oxo-butyric acid barium salt,

24. A method of treating neuroleptic diseases according to claim 18, wherein said neuroleptic active amount is an oral dosage in the amount of about 6 mgA per day to about 400 mgA per day.

25. A method according to claim 24 wherein said oral dosage is about 50 mgA per day to about 100 mgA per day.

26. A method of treating neuroleptic disease according to claim 18, wherein said neuroleptic active amount is a parenteral injection in the amount of about 30 mgA per day to about 200 mgA per day.

27. The method according to claim 26 wherein said amount is about 6.0 mgA per day to about 100 mgA per day.